Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS (Details)

v3.21.2
SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]                  
Revenues $ 1,010     $ 1,284     $ 7,773 $ 1,316  
Operating loss             (5,681)    
Financing expenses, net             (17,368)    
Share in losses of affiliated companies accounted for under equity method, net (1,007)     (734)     (1,499) (734)  
Net loss (10,379) $ 3,390 $ (17,557) $ (18,035) $ (2,585) $ (4,638) (24,547) $ (25,258)  
Total assets 17,161           17,161   $ 6,009
Total expenditures for assets of reportable segments             935    
Total depreciation for reportable segments             (526)    
Breast Cancer Test [Member]                  
Segment Reporting Information [Line Items]                  
Revenues                
Operating loss             (4,685)    
Total assets 10,257           10,257    
Total expenditures for assets of reportable segments             2    
Total depreciation for reportable segments             (22)    
Alzheimer [Member]                  
Segment Reporting Information [Line Items]                  
Revenues                
Operating loss                
Total assets              
Total expenditures for assets of reportable segments                
Total depreciation for reportable segments                
COVID-19 Testing [Member]                  
Segment Reporting Information [Line Items]                  
Revenues             7,773    
Operating loss             (996)    
Total assets $ 6,904           6,904    
Total expenditures for assets of reportable segments             933    
Total depreciation for reportable segments             $ (504)